“In this large genome-first study, the combined prevalence of pathogenic variants in key familial melanoma genes reached up to 0.9% in the general population and exceeded the 2.5% clinical testing threshold for individuals with multiple melanomas or early-onset disease.”

A groundbreaking 2026 study published in JAMA Dermatology provides fresh clarity on hereditary melanoma risk using unbiased, population-scale genomic data. For patients in the UK concerned about family history of skin cancer, these findings could reshape when and why genetic testing is recommended.

Key Areas We Will Cover

• Prevalence of pathogenic variants in familial melanoma genes in the UK and US populations
• Associated cancer risks, including cutaneous melanoma and internal malignancies
• Who should consider genetic testing according to the latest evidence
• Practical implications for dermatologic surveillance and cancer prevention in the UK
• How a Dermatologist can help interpret results and create a personalised risk management plan

Introduction

Familial melanoma genes play a significant role in inherited susceptibility to cutaneous melanoma and other cancers. This new research from large genomic cohorts, including UK Biobank data, offers important insights for UK patients. Understanding these genes helps individuals with a family history make informed decisions about testing and screening. At The Skin Care Network, our Dermatologist team in Barnet translates such advances into practical, patient-focused care.

What Are the Main Familial Melanoma Genes and Their Prevalence?

The 2026 JAMA Dermatology study analysed 696,665 genomically ascertained individuals and identified pathogenic variants (PVs) in eight key genes: ACD, BAP1, CDKN2A, CDK4, MITF E318K, POT1, TERF2IP, and TERT promoter.

Combined prevalence ranged from 0.5% (US cohort) to 0.9% (UK Biobank). The MITF E318K variant was most common (0.4–0.8%), followed by CDKN2A, POT1, and BAP1. Rarer variants in ACD, CDK4, and TERF2IP occurred at very low frequencies.

These findings indicate that while these variants are uncommon in the general population, they become clinically relevant in people with personal or family history of melanoma.

Who Should Consider Germline Testing for Familial Melanoma Genes?

Testing is particularly important for individuals with multiple cutaneous melanomas or a first melanoma diagnosed before age 40. In the study, prevalence in these high-risk groups exceeded the 2.5% threshold commonly used to recommend genetic testing.

A Dermatologist can assess your personal and family history to determine whether testing is appropriate. At our Barnet clinic, we guide patients through this process with clear, evidence-based recommendations.

What Cancer Risks Are Associated with These Genes?

CDKN2A variants were linked to increased risks of cutaneous melanoma, pancreatic cancer, brain tumours, head and neck cancers, and additional associations including biliary tract, breast, and non-melanoma skin cancers. Carriers often developed melanoma at younger ages.

MITF E318K showed associations with cutaneous melanoma, kidney cancer, and non-melanoma skin cancers.

POT1 variants were associated with cutaneous melanoma, haematologic malignancies, and thyroid cancer.

BAP1 showed links to prostate cancer (novel finding) alongside established risks such as mesothelioma and kidney cancer.

These results suggest the spectrum of associated cancers may be broader than previously recognised, supporting more comprehensive surveillance for carriers.

How Does This Affect Skin Surveillance and Prevention?

Carriers of CDKN2A and MITF E318K variants tended to develop melanoma earlier, often in the fourth decade. The study supports initiating regular dermatologic surveillance around age 30 for confirmed carriers.

In the UK, where melanoma incidence has stabilised in younger groups but remains a concern in older populations, enhanced awareness and professional skin checks are vital. Our Dermatologist at The Skin Care Network offers tailored surveillance programmes, including total-body skin examinations and mole mapping.

Address: 68-70 Union St, Barnet EN5 4HZ, United Kingdom

What Should UK Patients Do Next?

If you have a personal history of multiple melanomas, early-onset melanoma, or a strong family history, speak with a Dermatologist about genetic counselling and testing. These steps can inform personalised prevention strategies and potentially earlier detection of associated internal cancers.

Conclusion

This 2026 genome-first study provides valuable data on the prevalence and cancer risks linked to familial melanoma genes. It reinforces the importance of targeted genetic testing and highlights opportunities for improved risk assessment and surveillance. While most people will not carry these variants, those who do can benefit from proactive dermatologic care.

Get Started Today

Take control of your skin health with expert guidance. Book a consultation with a Dermatologist at The Skin Care Network to discuss your family history, risk assessment, and personalised surveillance plan.

📞 Call +44 20 8441 1043 or visit our clinic at 68-70 Union St, Barnet EN5 4HZ. Early action saves lives.

Frequently Asked Questions